MORPHOTEK
Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr.... Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.
MORPHOTEK
Industry:
Biotechnology Innovation Management Medical
Founded:
1999-01-01
Address:
Exton, Pennsylvania, United States
Country:
United States
Website Url:
http://www.morphotek.com
Total Employee:
51+
Status:
Active
Contact:
(610) 423-6100
Total Funding:
78.5 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS DocuSign Cisco Ironport Cloud Internet Names For Business XO Communications
Similar Organizations
Current Advisors List
Board_member
Current Employees Featured
Nicholas Nicolaides Founder @ Morphotek
Founder
Rodney E Dausch CFO @ Morphotek
CFO
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2011-03-04 | TransMolecular | TransMolecular acquired by Morphotek | N/A |
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Morphotek
Hunt BioVentures
Hunt BioVentures investment in Series D - Morphotek
CB Health Ventures
CB Health Ventures investment in Series D - Morphotek
SR One
SR One investment in Series D - Morphotek
Flagship Pioneering
Flagship Pioneering investment in Series D - Morphotek
MDS Capital
MDS Capital investment in Series D - Morphotek
Forward Ventures
Forward Ventures investment in Series D - Morphotek
Investor Growth Capital Limited
Investor Growth Capital Limited investment in Series D - Morphotek
Rock Maple Ventures
Rock Maple Ventures investment in Series D - Morphotek
Morgenthaler Ventures
Morgenthaler Ventures investment in Series D - Morphotek
Official Site Inspections
http://www.morphotek.com
- Host name: 162-244-194-226.bobbroadband.com
- IP address: 162.244.194.226
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Morphotek"
Morphotek - Crunchbase Company Profile & Funding
Morphotek is a biotech company that uses gene evolution technology to develop protein and antibody products. View contacts for Morphotek to access new leads and connect with …See details»
EISAI TO ACQUIRE MORPHOTEK Eisai's Dramatic Leap ... - Eisai …
Mar 22, 2007 · Morphotek develops therapeutic monoclonal antibodies through the use of proprietary human antibody technologies, including Human MORPHODOMA® and …See details»
Morphotek Company Profile 2024: Valuation, Investors …
Developer of therapeutic monoclonal antibodies for the treatment of cancer, inflammatory, and infectious diseases. The company conducts research and clinical development programs on its own drug candidates for ailments such …See details»
Eisai Announces Completion of Acquisition of Morphotek
Apr 17, 2007 · Morphotek develops therapeutic monoclonal antibodies through the use of its proprietary human antibody technologies, Human MORPHODOMA® and Libradoma™. The …See details»
Morphotek, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Morphotek, Inc. with its drug pipeline, therapeutic area, technology platform, 33 clinical trials, and 80 literature, Disease Domain:Neoplasms, Infectious Diseases, Technology …See details»
Morphotek Inc - Company Profile and News - Bloomberg Markets
Morphotek, Inc. operates as a life science industry. The Company offers biological-based products to treat cancer, inflammation, and infectious diseases. Morphotek serves clients in the...See details»
Morphotek - Flagship Pioneering
Morphotek, founded in 2001, was a biopharmaceutical company developing optimized therapeutic monoclonal antibodies through the use of its proprietary human antibody platform. The …See details»
Eisai to Acquire Morphotek for US $325 Million
Mar 22, 2007 · Eisai Co., Ltd., Eisai Corporation of North America (ECA) and Morphotek® Inc. announce that ECA has signed a definitive agreement to acquire Morphotek for (US) $325 …See details»
Morphotek - Funding, Financials, Valuation & Investors - Crunchbase
Morphotek is a biotech company that uses gene evolution technology to develop protein and antibody products.See details»
Morphotek - Contacts, Employees, Board Members, Advisors
Morphotek is a biotech company that uses gene evolution technology to develop protein and antibody products.See details»
Morphotek®, Inc. Opens 60,000-square-foot Manufacturing Plant
EXTON, Pa., Aug. 14, 2012 / PRNewswire / -- Morphotek (®), Inc., a wholly-owned subsidiary of Eisai Co., Ltd., today celebrated the grand opening of a new pilot manufacturing plant for the …See details»
MORPHOTEK, INC. ACQUIRES TUMOR TARGETING ASSETS FROM …
Apr 5, 2011 · Through use of the tumor targeting peptide (TTP) platform, it is possible to deliver active TTP conjugates directly to tumor cells via systemic administration of radionucleotides, …See details»
Morphotek®, Inc. Announces Initiation Of Amatuximab Study In …
Nov 18, 2015 · Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel …See details»
Morphotek Announces FDA Acceptance Of Investigational New …
Jan 10, 2018 · MORAb-202 is a novel investigational ADC that uses a cathepsin-cleavable linker to combine investigational farletuzumab with the microtubule inhibitor payload, eribulin. …See details»
FDA Grants Orphan Drug Status To Morphotek's Amatuximab …
EXTON, Pa., Nov. 12, 2012 / PRNewswire / -- Morphotek (® )Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted …See details»
Morphotek - Updates, News, Events, Signals & Triggers
Oct 4, 2016 · Morphotek is a biotech company that uses gene evolution technology to develop protein and antibody products.See details»
Biocare Medical Announces Agreement with Morphotek®, Inc. To …
Under the agreement, the parties will collaborate to develop and commercialize an immunohistochemical (IHC) diagnostic kit utilizing Morphotek’s proprietary monoclonal …See details»
Morphotek®, Inc. Announces A License Agreement With Blaze …
Nov 9, 2015 · Under the agreement, Morphotek provides to Blaze an exclusive, worldwide, royalty-bearing license to develop, license, and once approved, commercialize a potential …See details»
Morphotek®, Inc. Announces Initiation Of Farletuzumab Study In …
EXTON, Pa., March 30, 2015 /PRNewswire/ -- Morphotek ®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in a randomized, double-blind study of...See details»
Morphotek Raises $40 Million to Advance Its Antibody Pipeline
Oct 13, 2006 · Morphotek's lead antibody, MORAb-003, specifically targets the folate receptor alpha, a cell surface receptor over-expressed on ovarian, breast, colorectal, lung and renal …See details»